EQS-Adhoc: IGEA Pharma N.V.: IGEA Pharma support Italian COVID-19 battle

EQS Group-Ad-hoc: IGEA Pharma N.V. / Key word(s): Miscellaneous 
IGEA Pharma support Italian COVID-19 battle 
 
18-March-2020 / 20:00 CET/CEST 
Release of an ad hoc announcement pursuant to Art. 53 KR 
The issuer is solely responsible for the content of this announcement. 
 
*IGEA Pharma support Italian COVID-19 battle* 
 
Hoofddorp, the Netherlands, 18 March 2020. IGEA Pharma (SIX: IGPH) today 
announced an explosion in the demand for dry aerosol devices in Italy as a 
result of the COVID-19 outbreak so severely affecting this country. 
 
IGEA operates in air and surfaces sanitization with aerosol technology-based 
devices following the understandings on the acquisition of privately held 
Medical Jet. Vincenzo Moccia, CEO of IGEA: "The proven action of our aerosol 
solutions together with Rely+On Virkon(R) in reducing a broad spectrum of 
viruses and bacteria is highly appreciated. We remain fully committed to 
contribute in solving the problems of contamination of the air and the 
surfaces in the environments with high infections and life-threatening 
risk". 
 
The demand for aerosol solutions in Italy increased by 20 times compared to 
historic demand. As a result, IGEA and Medial Jet are enhancing the 
production capacities. 
 
*** 
 
*About IGEA* 
IGEA Pharma focuses on health-tech and med-tech products and devices. 
Health-tech products are exclusively preventative. IGEA commercializes an 
Alzheimer's prevention set (which includes 'Alz1', an at-home lab test kit 
to measure non-bound copper in the blood and 'Alz1 Tab', a natural dietary 
supplement designed to reduce blood heavy metals content) and expects to 
launch a diabetes type II prevention set in 2020. Non-ceruloplasmin bound 
copper is an expected Alzheimer's and diabetes type II associated biomarker. 
Determining and regulating non-bound copper can contribute to reduce the 
risk of Alzheimer's and diabetes type II. Med-tech products focuses on 
selected solutions and specialities. IGEA operates in air and inanimate 
environmental surface sanitization with aerosol technology-based devices and 
expects to start commercializing polymeric based infusion and transfusion 
solutions during 2020. 
 
IGEA is listed on the SIX Swiss Exchange (ticker IGPH) and is headquartered 
in Hoofddorp, the Netherlands. Find out more at www.igeapharma.nl 
 
*Contacts* 
Vincenzo Moccia, CEO Patrick Pozzorini, CFO 
Phone: [phone] Phone: [phone] 
41 43 
[e-mail] [e-mail] 
[e-mail] 
 
*Disclaimer* 
This document constitutes neither an offer to buy nor to subscribe 
securities and neither this document nor any part of it should form the 
basis of any investment decision in IGEA. 
 
The information contained in this press release has been carefully prepared. 
However, IGEA bears and assumes no liability of whatever kind for the 
correctness and completeness of the information provided herein. IGEA does 
not assume an obligation of whatever kind to update or correct information 
contained in this press release whether as a result of new information, 
future events or for other reasons. 
 
This publication may contain specific forward-looking statements and 
assessments or intentions concerning IGEA and its business. Such 
forward-looking statements are subject to known and unknown risks, 
uncertainties and other factors which may result in a substantial divergence 
between the actual results, financial situation, development or performance 
of IGEA and those explicitly or implicitly presumed in these statements. 
Against the background of these uncertainties, readers should not rely on 
forward-looking statements. IGEA assumes no responsibility to update 
forward-looking statements or to adapt them to future events or 
developments, except as may be required by law. 
 
End of ad hoc announcement 
Language:    English 
Company:     IGEA Pharma N.V. 
             Siriusdreef 17 
             2123 WT Hoofddorp 
             Netherlands 
Phone:       [phone] 
E-mail:      [e-mail] 
Internet:    www.igeapharma.nl 
ISIN:        NL0012768675 
Listed:      SIX Swiss Exchange 
EQS News ID: 1001235 
 
End of Announcement EQS Group News Service 
 
1001235 18-March-2020 CET/CEST 
 
 

(END) Dow Jones Newswires

March 18, 2020 15:00 ET (19:00 GMT)